Fig A. HRs with 95% CIs for age at menarche (per 1 year increase) on overall survival by clinicopathological subgroups.

Slides:

Advertisements

Similar presentations

Fig. 4-1, p Fig. 4-2, p. 109 Fig. 4-3, p. 110.

Advertisements

Integration of Capecitabine into Anthracycline- and Taxane-Based Adjuvant Therapy for Triple Negative Early Breast Cancer: Final Subgroup Analysis of the.

Time to Distant Metastases (ITT) Cumulative incidence of distant metastases (ITT) Adapted from Jones et al. SABCS 2008, abstract /477169/465253/454771/ /4146.

The 70-Gene Profile and Chemotherapy Benefit in 1,600 Breast Cancer Patients Bender RA et al. ASCO 2009; Abstract 512. (Oral Presentation)

P.464. Table 13-1, p.465 Fig. 13-1, p.466 Fig. 13-2, p.467.

Fig. 11-1, p p. 360 Fig. 11-2, p. 361 Fig. 11-3, p. 361.

Table 6-1, p Fig. 6-1, p. 162 p. 163 Fig. 6-2, p. 164.

Figure 1.1 The observer in the truck sees the ball move in a vertical path when thrown upward. (b) The Earth observer views the path of the ball as a parabola.

Memorial Sloan-Kettering Cancer Center

CaD TrialObservational Study All participantsNo Personal Supplements a Non-users ofCalcium +CalciumVitamin D PlaceboCaDPlaceboCaDSupplementsVitamin DOnly.

Vitamin D Deficiency is Common at Breast Cancer Diagnosis and is Associated with a Significantly Higher Risk of Distant Recurrence and Death in a Prospective.

Appendix Supplementary data (online only) to: Marleen Kok, Wilbert Zwart, Caroline Holm, Renske Fles, Michael Hauptmann, Laura J. Van ’t Veer, Lodewyk.

Principles of Hormonal Therapy Justus Apffelstaedt University of Stellenbosch These Power Point presentations are free to download only for academic purposes,

Personal Risk Factors Gender being a woman is the main risk factor for developing breast cancer (100 times more common in women) Age occurrence increase.

RT with TME surgery ? OUTLINEOUTLINE. Prostate Seminal vessels Neurovascular bundle Denonvilliers Fascia “holy plane” (Fascia rectalis) Total Mesorectal.

AVADO TRIAL David Miles Mount Vernon Cancer Centre, Middlesex, United Kingdom A randomized, double-blind study of bevacizumab in combination with docetaxel.

Rate of breast cancer-specific survival Months Low gene expression (N=252) High gene expression (N=37) P < (Log-rank) a Months Low gene expression.

Date of download: 5/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Adjuvant Chemotherapy With Gemcitabine and Long-term.

Date of download: 5/31/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Estrogen Plus Progestin and Breast Cancer Incidence.

CCO Independent Conference Coverage*: The 2015 Annual Meeting of the CTRC-AACR San Antonio Breast Cancer Symposium, December 8-12, 2015 San Antonio, Texas.

PHARE Trial Results of Subset Analysis Comparing 6 to 12 Months of Trastuzumab in Adjuvant Early Breast Cancer Pivot X et al. Proc SABCS 2012;Abstract.

CCO Independent Conference Coverage*: The 2015 Annual Meeting of the CTRC-AACR San Antonio Breast Cancer Symposium, December 8-12, 2015 San Antonio, Texas.

The Changing Face of Cancer in Iowa

Survivorship in Oncology

Triple Negative Breast Cancer versus Non-Triple Negative Breast Cancer Treated with Breast Conservation Surgery Followed by Radiotherapy: A Systematic.

Fig. 2. Kaplan-Meier curves for survival in each breast cancer molecular subtype. Radiologic assessment in triple-negative breast cancer (A), HER2-positive.

1.08 (0.77, 1.51) 0.93 (0.74, 1.16) 0.84 (0.63, 1.12) 1.29 (0.24, 6.91) 1.10 (0.80, 1.52) 0.93 (0.74, 1.17) 1.50 (0.27, 8.34) 1.12 (0.39, 3.23) 0.81 (0.60,

Fig. 1. Kaplan-Meir survival curves for Stoke Cushing's patients, with follow-up duration in years on the x-axis. Number of patients in each subgroup is.

Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: Focus on trabectedin Andrés Poveda, Isabelle Ray-Coquard, Ignacio Romero,

OVERALL LEADING CAUSES OF DEATH IN THE USA

The Clinical Significance of Uric Acid and Complement Activation in the Progression of IgA Nephropathy Kidney Blood Press Res 2016;41: DOI: /

Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study Liver Cancer.

Endometrial cancer on the rise in older women (August 2014)

Local Breast Cancer Recurrence after Mastectomy and Breast-Conserving Surgery for Paget's Disease: A Meta-Analysis Breast Care 2014;9: DOI: /

Diverticular Bleeding of the Colon during Combination Chemotherapy with Bevacizumab and Paclitaxel for Recurrent Breast Cancer Case Rep Oncol 2013;6:50–54.

Novel Pretreatment Scoring Incorporating C-reactive Protein to Predict Overall Survival in Advanced Hepatocellular Carcinoma with Sorafenib Treatment Liver.

Oncol Res Treat 2016;39: DOI: /

Figure 1. Overall survival of patients receiving alternative medicine (solid lines) vs conventional cancer treatment (dashed lines). Overall survival of.

Figure 2. A consort diagram showing the flowchart of the trial

Prognosis of younger patients in non-small cell lung cancer

The example of search strategy

Supporting Information for Meta-analysis

IHC-breast cancer subtypes of invasive ductal carcinoma with predominant intraductal component as an insignificant prognostic factor: A register-based.

Electrochemotherapy in the Treatment of Massive, Multisite Breast Cancer Metastasis to the Skin and Subcutaneous Tissue: A Case Report Breast Care 2016;11:

Supporting Information for Meta-analysis

Bronx Community Health Dashboard: Breast Cancer Last Updated: 1/19/2018 See last slide for more information about this project. While breast.

Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combined results.

سرطان الثدي Breast Cancer

Barrios C et al. SABCS 2009;Abstract 46.

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic.

Adjuvant Dose-Dense Chemotherapy in Breast Cancer: Standard of Care in High-Risk Patients Breast Care 2016;11: DOI: / Fig. 1. Strategies.

Program Goals. Single vs Dual HER2 Blockade for Metastatic HER2-Positive Breast Cancer.

Yearly colonoscopy, liver CT, and chest radiography do not influence 5-year survival of colorectal cancer patients David Schoemaker, Robert Black, Lynne.

Volume 13, Issue 11, Pages (November 2012)

Bernard Rosner Channing Division of Network Medicine

Table 2. Progression-Free Survival

Adjuvant chemotherapy for rectal cancer – Authors' reply

The Road to Quality Improvement in HER2-Positive Breast Cancer

A B Yeom Supplementary Fig.2

Impact of (A): metastatic sites (bone metastasis±lymph node metastasis vs visceral metastasis), (B): PSA response, (C): AA drug exposure duration on overall.

Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: A longitudinal study using UK patient registry.

Patients who have received chemotherapy (n=60)

Disease-specific survival

Prenatal phthalate exposure associates with low regulatory T-cell numbers and atopic dermatitis in early childhood: Results from the LINA mother-child.

Volume 68, Issue 5, Pages (November 2005)

OVERALL LEADING CAUSES OF DEATH IN THE USA

HRs for type 2 diabetes by category of age at menarche in the EPIC-InterAct study. HRs for type 2 diabetes by category of age at menarche in the EPIC-InterAct.

Fig. 1. Classification of the Kaplan-Meier curves and Cox survival estimates for the OS of patients using the pSPC in Cohort_C and in the overall population.

Kaplan–Meier curves for PFS and OS (for patients treated with anti-PD-1/PD-L1 monotherapy). Kaplan–Meier curves for PFS and OS (for patients treated with.

Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.

Presentation transcript:

Fig A. HRs with 95% CIs for age at menarche (per 1 year increase) on overall survival by clinicopathological subgroups

Fig B. HRs with 95% CIs for duration of endogenous estrogen exposure (per 1 year increase) on disease-free survival of breast cancer by clinicopathological subgroups

Fig C. HRs with 95% CIs for number of children ≥4 vs. 2 on disease-free survival of breast cancer by clinicopathological subgroups

Fig D. HRs with 95% CIs for number of years since last birth <5 vs. ≥20 years on disease-free survival of breast cancer by clinicopathological subgroups